Costa, Luciano J. http://orcid.org/0000-0001-5362-2469
Iacobelli, Simona
Pasquini, Marcelo C.
Modi, Riddhi
Giaccone, Luisa
Blade, Joan
Schonland, Stefan
Evangelista, Andrea
Perez-Simon, Jose A.
Hari, Parameswaran
Brown, Elizabeth E.
Giralt, Sergio A.
Patriarca, Francesca
Stadtmauer, Edward A.
Rosinol, Laura
Krishnan, Amrita Y.
Gahrton, Gösta
Bruno, Benedetto
Article History
Received: 2 February 2020
Revised: 19 March 2020
Accepted: 25 March 2020
First Online: 14 April 2020
Compliance with ethical standards
:
: LJC: Consultancy (Karyopharm, Celgene, Amgen, Sanofi, Abbvie, GSK), Research Funding (Amgen, Janssen); Honoraria (Celgene, Janssen, Amgen). MCP Consultancy (Pfizer, Medigene, Amgen, Novartis), Research Funding (Kite Pharmaceuticals, BMS). JB: Advisory committee (Janssen, Celgene, Amgen, Takeda). SS Research Funding (Prothena, Takeda, Janssen), Honoraria (Prothena, Medac, Janssen). PH: Consultancy (Celgene, Takeda, BMS, Janssen, Kite Pharmaceuticals, Amgen, Spectrum, Abbvie), Honoraria (Celgene, Takeda, Janssen, Kite Pharmaceuticals, Sanofi, Abbvie), Research Funding (Celgene, Takeda, BMS, Kite Pharmaceuticals, Spectrum). SAG: Consultancy (Jazz Pharmaceuticals, Novartis, Takeda, Celgene, Kite Pharmaceuticals, Johnson & Johnson, Actinium, Amgen, Spectrum Pharmaceuticals), Research Funding (Takeda, Celgene, Johnson & Johnson, Actinium, Miltenyi, Amgen). FP: Membership on Advisory Committee (Takeda, Celgene, Janssen). AYK: Consultancy (Abbvie, Novartis, Celgene, Takeda), Research Funding (Abbvie, Novartis, Tmunity). GG: Consultancy (Fujimoto Pharmaceutical Corporation). The remaining authors declare that they have no conflict of interest.